Charles J. Link

Headshot of Charles J. Link

Adjunct

Adjunct Professor

My research group’s focus has been on translational research to move new approaches into clinical studies for cancer patients with few if any treatment options. I am collaborating with LIMR researchers to address new combination immunotherapy-based approaches to improve cancer treatment. This work will encompass basic mechanistic studies as well as possible clinical trials focused on illuminating new cryoimmune-based therapeutic principles.

Contact Us

cjrclink@gmail.com
View Google Scholar to learn more

About

  • 2022–present: Adjunct Professor, Lankenau Institute for Medical Research
  • 2020–present: Executive Chairman & Chief Medical Officer, Syncromune
  • 1999–2019: Co-founder, Chairman & CEO, NewLink Genetics
  • 1995–2013: Oncologist, Medical Oncology and Hematology Associates
  • 1993–2007: Director, Stoddard Cancer Research Institute
  • 1990–1993: Attending Physician, National Cancer Institute

Publications

  • Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. Zakharia Y, McWilliams RR, … Link CJ Jr, et al. J Immunother Cancer. 2021 Jun;9(6):e002057. doi: 10.1136/jitc-2020-002057.
  • Phase 1a study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. Nayak-Kapoor A, Hao Z, … Link CJ, et al. J Immunother Cancer. 2018 Jun 20;6(1):61.
  • Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomized, multicenter, double-blind, placebo-controlled, dose-response study. Heppner DG Jr, Kemp TL, … Link CJ, et al. Lancet Infect Dis. 2017 Aug;17(8):854-866.
  • A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. Regules JA, Beigel JH, … Link CJ, et al. N Engl J Med. 2017 Jan 26;376(4):330-341.
  • A phase I study of indoximod in patients with advanced malignancies. Soliman HH, Minton SE, … Link C, et al. Oncotarget. 2016 Apr 19;7(16):22928-38.
  • Infectious diseases. Link C Jr, Cohen J. The Ebola vaccine underdog. Science. 2014 Oct 31;346(6209):534.
  • IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1 methyl-tryptophan. Metz R, Rust S, Duhadaway JB, … Link CJ, Prendergast GC. Oncoimmunology. 2012 Dec 1;1(9):1460-1468.
  • Complete protection against melanoma in absence of autoimmune depigmentation after rejection of Gal expressing melanoma cells. Rossi GR, Unfer, RC, … Link CJ. Cancer Immunol Immunother, 2005;54: 999-1009.
  • Partial functional correction of xeroderma pigmentosum group A cells by suppressor tRNA. Panchal RG, Wang, S, … Link CJ. Human Gene Ther, 1999;10:2209-2219.
  • Retroviral transfer and expression of a humanized, red shifted Green Fluorescent Protein gene into human tumor cells. Levy J, Muldoon R, … Link CJ. Nature Biotech. 1996;14: 610-614.
  • Radioisotope concentrator gene therapy: A novel approach to localize systemically administered radiation for tumor imaging and therapy by transfer of the sodium/iodide symporter gene. Mandell R, Mandell LZ, Link, CJ. Cancer Res. 1999;59: 661-668.

Education and training

Education

  • MD
    Stanford University School of Medicine, Stanford CA
  • Fellowship, Medical Oncology
    National Cancer Institute

Academic titles

  • 2022–present: Adjunct Professor, Lankenau Institute for Medical Research
  • 2020–present: Executive Chairman & Chief Medical Officer, Syncromune
  • 1999–2019: Co-founder, Chairman & CEO, NewLink Genetics
  • 1995–2013: Oncologist, Medical Oncology and Hematology Associates
  • 1993–2007: Director, Stoddard Cancer Research Institute
  • 1990–1993: Attending Physician, National Cancer Institute